Safinamid_TK, HEK, hkk
Original notice title
Germany – Pharmaceutical products – Open-House-Rabattverträge 2026-06 - Safinamid
Opportunity Score
Why this score?
Opportunity
40 / 100
Complexity
30 / 100
Risk factors
No guaranteed volume or minimum purchase; the actual revenue depends on the number of prescriptions and competition.
Submission deadlines for timely pharmacy software inclusion are strict (3rd of previous month). Late submissions may de...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Tender facts
- Contracting authority
- Techniker Krankenkasse
- Country
- Germany
- CPV
- 33600000 - Pharmaceutical products
- Deadline
- Apr 29, 2027
Overview
Moderate opportunityKey Facts
- Supplies contract
- 1 lot
- Duration until Apr 2027
- Conclusion of non-exclusive discount agreements for Safinamid pharmaceutical products under §130a Abs. 8 SGB V.
- Contract covers all exchangeable finished medicinal products of the contractor.
Show full summary
Open-house discount agreement procedure for pharmaceutical product Safinamid, conducted by Techniker Krankenkasse (TK) on behalf of HEK and hkk. The goal is to conclude non-exclusive rebate contracts with all eligible pharmaceutical entrepreneurs. Contract duration max 12 months from 01.05.2026 to 30.04.2027. Participation possible at any time during the contract period. No individual negotiations; uniform conditions.
Risks
No guaranteed volume or minimum purchase; the actual revenue depends on the number of prescriptions and competition.
Submission deadlines for timely pharmacy software inclusion are strict (3rd of previous month). Late submissions may de...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Must be a pharmaceutical entrepreneur within the meaning of §4 Abs. 18 AMG for the offered medicinal products.
- Company seat must be in Germany, another EU member state, or EEA state (§9 Abs.2 AMG).
- Local representatives can only participate if they themselves are pharmaceutical entrepreneurs for the offered products.
Buyer
Location
Hamburg, DEU
Website
Identifier
992-80116-93
Activity
Health
Lots (1)
LOT-0001
Safinamid_TK, HEK, hkk
Discount agreement for Safinamid active ingredient. Scope covers all exchangeable finished medicinal products of the contractor as per framework agreement. Participation of HEK and/or hkk depends on lot designation.
Location
Duration
Category
Deadline
Award details
Die Krankenkassen verfolgen das Ziel, mit allen geeigneten pharmazeutischen Unternehmern Rabattverträge nach § 130a Abs. 8 SGB V über die im jeweiligen Los genannten Wirkstoffe, Wirkstoffkombinationen bzw. Darreichungsformen, Wirkstärken oder Fertigarzneimittel zu schließen.
Value note
Show original TED data
Original TED description
Die Krankenkassen verfolgen das Ziel, mit allen geeigneten pharmazeutischen Unternehmern Rabattverträge nach § 130a Abs. 8 SGB V über die im jeweiligen Los genannten Wirkstoffe, Wirkstoffkombinationen bzw. Darreichungsformen, Wirkstärken oder Fertigarzneimittel zu schließen.
Procurement Details
- Publication date
- 26 Mar 2026
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 214489-2026
Documents (1)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
40 / 100
Complexity
30 / 100
Risk factors
No guaranteed volume or minimum purchase; the actual revenue depends on the number of prescriptions and competition.
Submission deadlines for timely pharmacy software inclusion are strict (3rd of previous month). Late submissions may de...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications